Press Room

12th American DDF Summit - Drug Delivery and Formulation

Start
Monday, September 26, 2022 - 09:00
End
Tuesday, September 27, 2022 - 18:00
Location: San Diego, USA
Booth Number: 13
Hovione is the Official Partner of the 12th DDF USA Summit 2022

 

HOVIONE PRESENTATION

 

Pedro Valente | Hovione

 

September 27th

“Solution Spotlights – Technology & Innovation” session

with Pedro Valente

R&D Director - Oral Drug Product Development

 

 

Download a copy of the presentation

 

 

Streamlining end-to-end amorphous formulation development into a tablet suitable for Continuous Direct Compression

 

  •  Learn how bioavailability enhancement of Amorphous Solid Dispersions (ASDs) can vary from one to three orders of magnitude by optimizing both ASD and tablet formulations and processes
  • Learn how state-of-the-art tools and methodologies can shorten time to Phase I/IND by accelerating formulation and development process 
  • Learn how Dispersome(R) technology, based on natural proteins derived from milk, broaden the formulation landscape enabling high drug load and high performing formulations
  • Learn how ASD formulations manufactured by spray drying can be designed to be directly compressible by Continuous Tableting
  • Learn more how Continuous Tableting is enabling disruptive innovations in the Pharma industry with respect to quality, scalability and improving supply chain flexibility and broadening Lifecycle Management options

 

 

At Hovione we are constantly innovating to find better and more efficient ways of doing things.

 

  • If you are developing a novel drug formulation or improving your drug candidate, learn how the Dispersome® technology can increase drug solubility with clear benefits for patients

     
  • If you are looking for the most advanced and accurate screening platform able to identify the most efficient and stable Amorphous Solid Dispersion formulations by Spray Drying, learn more about ASD-HIPROS 

     

If you are interested in turning your most difficult challenge into a successful solution, schedule a meeting today to know how Hovione experts can support your project.

 

 

Find more at DDFSummit.com

 

 

Also in the Press Room

See All

Hovione is bringing momentum to the intranasal field after announcing that its lead single-use nasal dry powder device, developed in collaboration with Industrial Design Consultancy Ltd (IDC), is now available for commercial partnerships. The milestone marks the transition from prototype to a fully integrated intranasal drug delivery platform that spans Hovione’s end-to-end partnership capabilities–from API synthesis through advanced formulation and particle engineering to drug product manufacturing, including device supply and advanced analytical tools for nasal performance characterization. The platform’s single-use device is designed to be manufacturable at scale and to leverage existing advanced particle engineering and drug product manufacturing capabilities, a practical advantage that can shorten timelines to clinic and commercialization while reducing development risk and cost. The device’s patented mechanism supports targeted nasal deposition, including access to the upper olfactory region. This enables rapid systemic absorption and potential nose-to-brain delivery pathways that are increasingly important for CNS and emergency-use indications. Beyond the single-use format, Hovione and IDC are advancing a multi-dose variant to broaden applicability across dosing regimens and therapeutic areas. The collaboration is backed by an intellectual property portfolio and initial patent grants, positioning the platform as a turnkey option for pharma partners seeking a single integrated supplier for both drug substance and device. This development arrives as intranasal delivery gains traction for systemic, CNS and rapid-onset therapies. This is precisely the focus of the upcoming 4th Nasal Formulation & Delivery Summit, for which Hovione is a key sponsor. The annual summit unites formulation, delivery and product development leaders to tackle drug-device compatibility, translational preclinical models, and strategies for scalable, regulatory-ready intranasal programs. Hovione’s recent progress will be highly relevant to attendees looking to de-risk nose-to-brain and systemic intranasal programs. Read the full article at News-Medical.net    

Press Clipping

Hovione advances intranasal drug delivery with commercial-ready dry powder platform ahead of 4th Nasal Formulation & Delivery Summit

Jun 01, 2026